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Note 
 
Bad Blood: An Examination of the Constitutional 
Deficiencies of the FDA’s “Gay Blood Ban” 
Mathew L. Morrison* 
When twenty-six-year-old Evan Low was sworn in as the 
mayor of Campbell, California, he made headlines as the 
youngest Asian-American, openly gay mayor in the nation.
1
 As 
a result of his dedication to civic engagement, government 
transparency, and fiscal responsibility, Mayor Low enjoyed 
popularity and respect as a public servant.
2
 Mayor Low did not, 
however, receive similar treatment under the law as a gay 
man. Though Mayor Low now has access to rights that, until 
recently, were unavailable to him and other LGBT Americans, 
such as marriage and federal tax benefits, he is still barred 
from donating blood pursuant to federal policy which bans gay 
men from donating blood.
3
 Despite coordinating a blood drive 
 
  J.D. Candidate 2015, University of Minnesota Law School; B.A. 2012, 
Northwestern State University of Louisiana. Thank you to the professors who 
provided invaluable feedback on this note, including Professor Fred Morrison 
and Professor Dale Carpenter. Thank you also to the incredible mentors who 
have supported me through the years, including Dr. Holly Stave, Charlie 
Penrod, and Dr. Davina McClain. Many thanks to the staff and editors of 
Minnesota Law Review, my friends, and my family. Copyright © 2015 by 
Mathew L. Morrison. 
 1. Chris Vongsarath, Campbell’s Evan Low Sworn in As Youngest Asian-
American, Openly Gay Mayor in the Country, SAN JOSE MERCURY NEWS (Dec. 
2, 2009), http://www.mercurynews.com/breaking-news/ci_13909520. 
 2. Id.  
 3. Tracy Miller, California Mayor Calls for End to FDA Ban on Gay Male 
Blood Donations, DAILY NEWS (Aug. 21, 2013), http://www.nydailynews 
.com/life-style/health/calif-mayor-calls-gay-blood-donor-ban-article-1.1433054. 
The recent Supreme Court decision in United States v. Windsor furthered 
what many call the “gay rights” movement by striking down a key portion of 
the Defense of Marriage Act (DOMA), which discriminated against homosexu-
als as a class. Defense of Marriage Act, Pub. L. No. 104-199, § 3, 110 Stat. 
2419, 2419 (1996), invalidated by United States v. Windsor, 133 S. Ct. 2675, 
2695–96 (2013). Many states have also legalized gay marriage. Ryan L. 
Sievers, Same-Sex Marriage Is Legal in 16 States, and This Is Good, 
CHICAGONOW (Nov. 16, 2013, 12:41 AM), http://www.chicagonow.com/art-of 
-business/2013/ 
11/same-sex-marriage-is-good. 
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with the American Red Cross, Mayor Low was not allowed to 
donate blood at the event.
4
 The ban, enacted in 1983, prohibits 
all men who have had sex with other men (MSM) since 1977 
from donating blood, and is regarded by many as being unnec-
essarily discriminatory.
5
  
Mayor Low is only the latest in an ever-increasing line of 
individuals who have been banned from donating blood since 
the guideline was implemented in 1983.
6
 The Food and Drug 
Administration (FDA) currently prohibits MSM from donating 
blood due to concerns that, as a population, MSM are at a high-
er risk for carrying HIV, hepatitis B, and other diseases that 
are transmittable via blood transfusions.
7
 The FDA’s concern of 
assuring the safety of patients receiving blood was the primary 
impetus for the ban.
8
 The guideline was thus first implemented 
at the outset of the HIV/AIDS epidemic, when the disease was 
most rampant in the MSM community.
9
 Even as late as 2010, 
the MSM population accounted for 61% of new HIV infections, 
and 77% of male HIV infections were attributed to male-to-
male sexual contact.
10
 
Though the FDA currently cites statistics to justify its poli-
cies, many argue that the guidelines are now outdated and no 
longer based on “sound science.”
11
 Others contend that the ban 
is discriminatory and, as such, unconstitutional under U.S. 
law.
12
 The FDA disagrees with both arguments and to this day 
maintains its “gay blood ban.”
13
 Recent developments may see a 
 
 4. Miller, supra note 3. 
 5. See id. 
 6. See id. 
 7. Blood Donations from Men Who Have Sex with Other Men Questions 
and Answers, FDA, http://www.fda.gov/BiologicsBloodVaccines/BloodBlood 
Products/QuestionsaboutBlood/ucm108186.htm (last updated Mar. 8, 2015) 
[hereinafter FDA Guidelines]. For the sake of consistency, this Note will refer 
to the FDA’s policy as the “gay blood ban” throughout. Note that the FDA has 
recently indicated its willingness to alter the policy. See infra Part I.B. How-
ever, as this Note will discuss, this does not ameliorate the substantive prob-
lems of the current policy. 
 8. See FDA Guidelines, supra note 7. 
 9. See id.  
 10. Id.  
 11. Gillian Mohney, FDA Ban on Gay Men as Blood Donors Opposed by 
American Medical Association, ABC NEWS (June 20, 2013), http://abcnews 
.go.com/Health/american-medical-association-opposes-fda-ban-gay-men/story? 
id=19436366 (quoting American Medical Association board member Dr. Wil-
liam Kobler). 
 12. See Miller, supra note 3. 
 13. See FDA Guidelines, supra note 7 (contending that the guideline “is 
not based on any judgment concerning the donor’s sexual orientation,” and 
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modified ban implemented in the near future, but as this Note 
will discuss, those changes are insufficient. Despite the FDA’s 
attempts at justifying the ban, the fact remains that heterosex-
ual individuals who engage in risky sexual behavior, gay wom-
en, and other populations with potential exposure to HIV and 
other diseases face no such ban.
14
  
The gay blood ban raises several questions of law. This 
Note examines those issues and offers a solution that attempts 
to bridge the gap between the government’s need to ensure the 
safety of the blood supply while also respecting the dignity of 
an oft-maligned population. Part I discusses the background 
and rationale for the original implementation of the gay blood 
ban, as well as recent developments in science, society, and law 
that affect the issue. Part II briefly analyzes legal and norma-
tive questions raised by the ban before delving into the most 
viable challenge to the ban, based on constitutional principles 
of equality. Part III offers a new framework by which the FDA 
can effectively and in a nondiscriminatory manner regulate the 
nation’s blood supply. 
I.  DEVELOPMENT OF THE HIV EPIDEMIC AND 
SUBSEQUENT REGULATION   
Though HIV and AIDS are understood in the scientific 
community today, this was not always the case.
15
 This Part ex-
amines both the history of the HIV/AIDS epidemic and the sub-
sequent regulatory framework that arose as an attempt to pro-
tect the nation’s blood supply. Section A briefly recounts the 
history of the HIV/AIDS epidemic in the context of its associa-
tion as a “gay” disease as well as the developments in science 
and medicine that have led to current general knowledge of the 
virus. Section B discusses the history of the FDA’s regulatory 
approach to the HIV virus in the context of blood donations. 
A. HISTORY OF THE HIV/AIDS EPIDEMIC 
The association between gay men and HIV, and the fears 
consequently produced by the connection, were justified at one 
point. The beginning years of the epidemic in the United States 
were filled with confusion and uncertainty. Cases were report-
 
that currently cited statistics are sufficient evidence for continuing the ban).  
 14. Id.  
 15. AIDS is the syndrome of medical complications arising from an HIV 
infection. See generally What Is HIV/AIDS?, AIDS.GOV, http://www.aids.gov/ 
hiv-aids-basics/hiv-aids-101/what-is-hiv-aids (last updated Apr. 29, 2014) (ex-
plaining the relationship between HIV and AIDS).  
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ed as early as October of 1980, when an individual dubbed “Pa-
tient Zero” infected men at a New York City bath house with 
the virus that would eventually come to be known as HIV.
16
 The 
new disease was first acknowledged by the Centers for Disease 
Control (CDC) when it published reports of a rare lung infec-
tion, Pneumocystis carinii pneumonia (PCP), affecting several 
otherwise healthy young gay men in Los Angeles.
17
 Within days 
of the publication, doctors across the United States inundated 
the CDC with reports of similar infections in young gay men.
18
 
Subsequent reports of diseases in the gay community were not 
confined to PCP. Other diseases that were reported included 
Kaposi’s Sarcoma, an unusually aggressive cancer that until 
then was a rare occurrence.
19
 The infections were exclusive to 
gay men at this point.
20
 
The still-unknown disease affecting men mostly in New 
York and California became so associated with homosexuals 
that it was initially called the “Gay-related immune disease,” 
and this name gained some popularity until the occurrence of 
infections in heterosexual Haitians.
21
 Though other popula-
tions, such as hemophiliacs,
22
 soon joined homosexuals and 
Haitians as groups associated with the disease, in the public’s 
eye the disease was largely a homosexual problem.
23
 It was not 
until July of 1982 that the disease was officially renamed as 
“acquired immunodeficiency syndrome,” or AIDS.
24
 
When it became clear in 1982 that a new disease was rap-
idly spreading throughout the United States, several clinics 
and medical service organizations cropped up throughout the 
country, many emphasizing health services for gay men.
25
 At 
 
 16. AIDS in New York: A Biography, N.Y. MAG., http://nymag.com/ 
news/features/17158 (last visited Apr. 20, 2015).  
 17. A Timeline of AIDS, AIDS.GOV, http://aids.gov/hiv-aids-basics/hiv 
-aids-101/aids-timeline (last visited Apr. 20, 2015).  
 18. Id.  
 19. Id.  
 20. Id. 
 21. AIDS in New York, supra note 16.  
 22. Hemophilia is a blood disorder that prevents blood from clotting 
properly in wounds. As a result, hemophiliacs bleed for longer periods of time, 
which is not a problem for cuts but can become life-threatening with larger 
injuries. Hemophilia, MAYO CLINIC (Sept. 26, 2014), http://www.mayoclinic 
.org/diseases-conditions/hemophilia/basics/definition/con-20029824. 
 23. AIDS in New York, supra note 16.  
 24. Id.  
 25. A Timeline of AIDS, supra note 17. A few examples include New York 
City’s Gay Men’s Health Crisis, the nation’s first community-based HIV/AIDS 
service provider, the San Francisco AIDS Foundation, and the first American 
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this time, little was known about the disease, and Congress 
passed reactive legislation to fund surveillance and AIDS re-
search through the CDC and the National Institutes of 
Health.
26
 In April of 1982, the first CDC estimate of the popula-
tion affected by the disease numbered in the tens of thou-
sands.
27
 In late 1982, an AIDS infected donor transmitted the 
disease to an infant through a blood transfusion, causing the 
nation’s first panic over the blood supply.
28
  
The final straw concerning blood donations was conclusive 
research indicating that AIDS was transmitted through sexual 
contact and, potentially, blood transfusions.
29
 One 1983 Morbid-
ity and Mortality Weekly Report indicated that the occurrence 
of AIDS cases paralleled that of another sexually transmitted 
disease, hepatitis B, and that “[t]he likelihood of blood trans-
mission is supported by the occurrence of AIDS among IV drug 
abusers.”
30
 At this time, there was no way to detect AIDS in 
asymptomatic patients, and the precise cause was still un-
known.
31
 Though the Report outlined some ways by which to 
reduce risk of infection, it conceded that, until AIDS was better 
understood by the medical community, the organization’s abil-
ity to detect and prevent the disease was “somewhat compro-
mised.”
32
 
With widespread awareness of AIDS came concern over the 
nation’s blood supply. Already fueled by cases of infection 
through blood transmission, the CDC initially recommended 
that all at-risk populations, such as intravenous drug users and 
MSM, refrain from donating blood or plasma.
33
 According to the 
FDA, 1983 marked the first time that the MSM population was 
 
AIDS clinic, established in San Francisco. Id.  
 26. Id.  
 27. Id.  
 28. AIDS in New York, supra note 16.  
 29. CDC, Current Trends Prevention of Acquired Immune Deficiency Syn-
drome (AIDS), 32 MORBIDITY & MORTALITY WKLY. REP. 101 (Mar. 4, 1983), 
available at http://www.cdc.gov/mmwr/preview/mmwrhtml/00001257.htm.  
 30. Id.  
 31. Id. 
 32. Id. 
 33. Id. Though blood donation guidelines had not yet been affected by con-
cern for the blood supply, signs were already indicating that the FDA was pre-
paring a guidelines overhaul. Id. (“The Food and Drug Administration (FDA) 
is preparing new recommendations for manufacturers of plasma derivatives 
and for establishments collecting plasma or blood. This is an interim measure 
to protect recipients of blood products and blood until specific laboratory tests 
are available.”). 
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singled out and discouraged from donating,
34
 though the ban 
would not become codified in FDA regulations until 1992.
35
 
Though undeveloped guidelines were implemented in 1983, the 
response of the FDA and the blood banking industry was highly 
criticized as “woefully inept” and ineffective at initially protect-
ing the blood supply.
36
 Given that the precise viral origin of 
AIDS was still unknown, there was no way to screen for infect-
ed blood, and so deferral
37
 of the MSM population eventually 
gained traction as the next best viable option.
38
 
The “blood ban” did not originally apply to all individuals 
in the MSM population. Initially, the Public Health Service on-
ly identified homosexual and bisexual men who had multiple 
sex partners as one of the high-risk groups, and accordingly 
recommended that they defer from donating.
39
 Though some 
groups argued that the recommendation went too far in dis-
criminating against the gay male population, others criticized 
the ban for not going far enough.
40
 Eventually, the FDA issued 
guidelines meant to serve as a temporary fix, and the gay 
community reluctantly acquiesced to the policy.
41
 In 1992, how-
ever, the ban became permanent, and the FDA instituted a life-
time blood donation ban on the MSM population without re-
gard to other factors, such as number of sex partners or history 
of drug use.
42
 Given the ominous danger of infection through 
blood transfusions,
43
 the subsequent public health concerns, 
 
 34. See Shawn Carroll Casey, Illicit Regulation: A Framework for Chal-
lenging the Procedural Validity of the “Gay Blood Ban,” 66 FOOD & DRUG L.J. 
551, 551 (2011) (noting that, at first, the CDC only “recommended” that high 
risk groups, including MSM, be asked to defer from donating).  
 35. FDA Guidelines, supra note 7. As a federal agency, the FDA has the 
power to make rules. 5 U.S.C. § 553 (2012). Several laws give the FDA the au-
thority to specifically regulate the nation’s blood supply. Food, Drug, and 
Cosmetics Act, 21 U.S.C. § 301 (2012); Public Health Service Act, 42 U.S.C. 
§ 201 (2012); Biologies Act, 42 U.S.C. § 262 (2012).  
 36. See Linda M. Dorney, Culpable Conduct with Impunity: The Blood In-
dustry and the FDA’s Responsibility for the Spread of AIDS Through Blood 
Products, 3 J. PHARMACY & L. 129, 130 (1994). 
 37. For the purposes of this Note, the “gay blood ban” refers to the FDA’s 
current policy, supra note 7, and a “deferral” refers to any period of time an 
MSM must abstain from having sexual relations in order to donate blood (for 
example, a one year period). 
 38. See Casey, supra note 34, at 554. 
 39. CDC, supra note 29. 
 40. Casey, supra note 34, at 554–56. 
 41. See id. at 555. 
 42. See FDA Guidelines, supra note 7. 
 43. See Francine A. Hochberg, HIV/AIDS and Blood Donation Policies: A 
Comparative Study of Public Health Policies and Individual Rights Norms, 12 
DUKE J. COMP. & INT’L L. 231, 235 (2002) (“[T]he success of HIV transmission 
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and general ignorance of how the disease worked, as well as 
how to screen it, the ban, at the time it was implemented, was 
the best way to prevent the spread of AIDS.
44
  
B. A NEW REGULATORY REGIME: RESPONSES TO THE HIV/AIDS 
EPIDEMIC  
As science and technology change, so do societal views. In 
some instances, the legal landscape reflects these alterations. 
Fifteen years ago, the concept of same-sex marriage was a nov-
el idea and far from reality; today thirty-seven states and the 
District of Columbia have legalized same-sex marriage.
45
 Simi-
larly, the evolving landscape of medical knowledge, or the lack 
thereof, greatly impacted HIV/AIDS regulation across the 
board and continues to do so.
46
 This Section recounts the histo-
ry of the regulatory framework arising out of the HIV/AIDS ep-
idemic. It also discusses the FDA’s recent statements regarding 
a potential policy change—one that still raises the problems of 
the lifetime ban. 
As AIDS became more widespread throughout the country, 
so did the impetus to understand the disease. It was no longer 
a mysterious illness affecting a small population, rather, “the 
greatest tragedy of the twentieth century.”
47
 With the drive to 
understand the new killer disease came a wealth of scientific 
information and, eventually, the development of technologies 
that led to a better understanding of how AIDS worked and 
how to prevent its transmission.
48
 
 
is over 90% when infected blood is transfused to a formerly uninfected per-
son.”) (citing BARRY D. SCHOUB, AIDS AND HIV IN PERSPECTIVE: A GUIDE TO 
UNDERSTANDING THE VIRUS AND ITS CONSEQUENCES 111, 114 (2d ed. 1999)).  
 44. See Mike Darling, Banned for Life, MEN’S HEALTH (2013), http:// 
www.menshealth.com/banned-for-life (noting that there was no viable way of 
testing blood or plasma for HIV at the time the bans were implemented).  
 45. See Same-Sex Marriage Laws, NAT’L CONF. ST. LEGISLATURES (Feb. 
19, 2015), http://www.ncsl.org/research/human-services/same-sex-marriage 
-laws.aspx. The issue of same-sex marriage continues to be in the spotlight, as 
the Sixth Circuit recently upheld bans against same-sex marriage, creating 
the first circuit split on the issue. Id.  
 46. For instance, current laws criminalizing knowing infection of sexual 
partners with HIV has in recent years been criticized as the landscape has 
shifted. See generally Kim Shayo Buchanan, When Is HIV a Crime? Sexuality, 
Gender and Consent, 99 MINN. L. REV. 1231 (2015) (arguing that decriminali-
zation would best address the “discriminatory social meaning and effects of 
HIV criminalization”).  
 47. Muser Entertainment, Madonna - In This Life (The Girlie Show), 
YOUTUBE (Mar. 7, 2009), http://www.youtube.com/watch?v=7sBOxrsCmPo 
(dedicating a song to her friends who died from AIDS).  
 48. See generally Mohney, supra note 11 (discussing the request of the 
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In 1985, shortly after acceptance of the MSM donor ban be-
came mainstream, HIV was officially identified as the retrovi-
rus responsible for AIDS.
49
 Following this discovery, the FDA 
licensed a test for the purpose of detecting HIV’s presence in 
donated blood and blood products, known as the enzyme-
linked-immuno-sorbent-assay, or ELISA.
50
 Though this test was 
a breakthrough, estimates indicated that adding the test to the 
blood collection process would be expensive.
51
 In the midst of 
this developing technology and increasing ability to test accu-
rately for HIV/AIDS, the FDA tightened its donation policy in 
1992.
52
 The resulting policy banned all men who had engaged in 
sexual activities with other men since 1977 from donating 
blood.
53
 Though the ELISA test was the beginning, it certainly 
was not the most effective method of HIV detection.
54
 As recent-
ly as 2012, a testing method known as Nucleic Acid Testing 
(NAT) has been offered as a more effective method of HIV de-
tection.
55
 It is more accurate and yields quicker results.
56
 In-
stead of testing for HIV antibodies, NAT uses primers that 
identify RNA or DNA in blood samples as HIV-1 RNA, and is 
used for detecting other diseases as well.
57
 Studies indicate that 
NAT testing has increased HIV detection yield by 23%.
58
 
With an ever-increasing body of knowledge and technology 
better equipped to test for the virus in blood samples, the gay 
 
U.S. Department of Health and Human Services for “information from addi-
tional studies on the potential outcomes of changing the blood donation crite-
ria”). 
 49. Casey, supra note 34, at 556. 
 50. See Doe v. Am. Nat’l Red Cross, 866 F. Supp. 242, 244–45 (D. Md. 
1994).  
 51. See id. at 245. 
 52. Casey, supra note 34, at 556. 
 53. Id. 
 54. See generally FDA, GUIDANCE FOR INDUSTRY USE OF NUCLEIC ACID 
TESTS ON POOLED AND INDIVIDUAL SAMPLES FROM DONORS OF WHOLE BLOOD 
AND BLOOD COMPONENTS, INCLUDING SOURCE PLASMA, TO REDUCE THE RISK 
OF TRANSMISSION OF HEPATITIS B VIRUS (2012), available at http://www. 
fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatory 
Information/Guidances/Blood/UCM327895.pdf.  
 55. Id. Various iterations of the test were first licensed by the FDA for use 
beginning in 2006 or so, but the FDA began to encourage their use much later. 
Id. 
 56. See Debra Kain, Adding Nucleic Acid Testing to HIV Screening May 
Help Identify More People with HIV, UC SAN DIEGO NEWS CENTER (June 15, 
2010), http://ucsdnews.ucsd.edu/archive/newsrel/health/06-15TestingHIV.asp.  
 57. FDA, supra note 54, at 2. 
 58. Kain, supra note 56. 
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blood ban is losing popularity in the medical community
59
 and 
general population.
60
 Other countries, which previously had fol-
lowed the United States’ lead in instituting lifetime bans, have 
now lifted those bans partially or entirely.
61
 As early as 1992, 
the Department of Health and Human Services indicated that 
HIV infections represented only a “minimal” risk to the blood 
supply.
62
 The Health and Human Service’s Advisory Committee 
on Blood Safety and Availability (ACBSA) recently found that 
the current donation policies, while effective at excluding some 
high risk donors, also potentially excludes low risk donations, 
and as such has recommended a reevaluation of the current 
guideline.
63
 The FDA ardently opposes updating its current pol-
icy, however, stating that it would “change this policy only if 
supported by scientific data showing that a change in policy 
would not present a significant and preventable risk to blood 
recipients.”
64
 The FDA maintains that there is no threat to the 
blood supply, that the MSM population remains the most high-
 
 59. See Mohney, supra note 11 (noting that the American Medical Associ-
ation now opposes the ban, arguing that “‘[t]he lifetime ban on blood donation 
for men who have sex with men is discriminatory and not based on sound sci-
ence’” (quoting AMA board member Dr. William Kobler)).  
 60. See Darling, supra note 44; Tyler Smith, Gay Blood Considered Risk 
for Donation, FOURTH EST. (Sept. 6, 2013), http://www.fourthestatenewspaper 
.com/opinion/2013/09/06/gay-blood-considered-risk-for-donation. 
 61. See generally Clive R. Seed et al., No Evidence of a Significantly In-
creased Risk of Transfusion-Transmitted Human Immunodeficiency Virus in 
Australia Subsequent to Implementing a 12-Month Deferral for Men Who Have 
Had Sex with Men, 50 TRANSFUSION 2722 (2010); Philip Caulfield, Britain To 
Allow Gay Men To Donate Blood, DAILY NEWS (Apr. 10, 2011, 11:46 AM), 
http://www.nydailynews.com/news/world/Britain-gay-men-donate-blood-policy-
step-u-s-ban-gay-donors-article-1.110214 (reporting that Britain will institute 
a ten-year deferral period in place of the previous lifetime ban); Scott Roberts, 
Mexico Lifts Ban on Gay Men Donating Blood, PINK NEWS (Dec. 27, 2012, 6:29 
PM), http://www.pinknews.co.uk/2012/12/27/mexico-lifts-ban-on-gay-men 
-donating-blood (“Gay and bisexual men, who have a history of using condoms, 
who do not inject drugs, and are not sex workers can now donate.”); Elizabeth 
Trovall, Gays and Lesbians in Chile Now Allowed To Donate Blood, SANTIAGO 
TIMES (Apr. 25, 2013), http://www.archive.today/KNJUm (reporting a lift of 
Chile’s current ban with no time deferrals).  
 62. Memorandum from the Dir. of the Ctr. for Biologics Evaluation & Re-
search to All Registered Blood Establishments, Revised Recommendations for 
the Prevention of Human Immunodeficiency Virus (HIV) Transmission by 
Blood and Blood Products (Apr. 23, 1992) (on file with the FDA), available at 
http://www.fda.gov/downloads/UCM062834.pdf.  
 63. FDA Guidelines, supra note 7.  
 64. Id. There was also considerable doubt as to whether the FDA could 
change this policy even if it had the desire to do so without going through the 
arduous notice and comment procedure. See Paralyzed Veterans of Am. v. D.C. 
Arena L.P., 117 F.3d 579, 586 (D.C. Cir. 1997); infra Part II.B.2. 
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ly susceptible to HIV infection, and that testing technology is 
not adequate to justify a lift on the ban.
65
 
Though the FDA argues that the MSM population is still 
high risk to the point of justifying a ban, it has indicated a will-
ingness to modify its policy. On December 23, 2014, the FDA 
issued a statement indicating that, in light of scientific data 
and the recommendations of advisory committees to the U.S. 
Department of Health and Human Services (HHS), it will soon 
consider altering the ban.
66
 Specifically, the FDA is willing to 
“change . . . the blood donor deferral period for men who have 
sex with men from indefinite deferral to one year since the last 
sexual contact.”
67
 Taking note of its prior error in implementing 
the lifetime ban, the FDA plans to initiate the appropriate no-
tice and comment procedure.
68
 
Substantively, this development does little, if anything, to 
improve the current state of affairs for gay and bisexual men. 
The notice and comment procedure does not guarantee that the 
FDA will implement the new policy, only that it will consider 
its implementation. Further, the FDA will not consider lifting 
the ban in its entirety.
69
 For some, this may appear to be pro-
gress. But this is the bottom line: the best case scenario sees 
the FDA implementing a one-year deferral period specifically 
addressing the MSM population; the worst case scenario sees 
no change in the policy if the notice and comment procedure re-
sults in enough opposition to the proposed change. Despite its 
 
 65. See infra Part II.B.2. 
 66. FDA Commissioner Margaret A. Hamburg’s Statement on FDA’s Blood 
Donor Deferral Policy for Men Who Have Sex with Men, FDA (Dec. 23, 2014), 
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427843 
.htm [hereinafter FDA Statement].  
 67. Id. 
 68. Id. (“The FDA intends to issue a draft guidance recommending this 
proposed change in policy in 2015, which will also include an opportunity for 
public comment. We encourage all stakeholders to take this opportunity to 
provide any information the agency should consider, and look forward to re-
ceiving and reviewing these comments.”).  
 69. The FDA has already indicated an extreme reluctance in even altering 
the policy. See FDA Panel Wary of Lifting Ban on Gay Blood Donors, 
WTSP.COM (Dec. 3, 2014, 4:26 PM), http://www.wtsp.com/story/news/health/ 
2014/12/03/fda-panel-wary-of-lifting-ban-on-gay-blood-donors/19851057 (stat-
ing that the FDA’s experts did not embrace even the twelve-month deferral 
period proposal). One FDA official stated, “If I look at the science I would be 
very wary of a one-year deferral . . . . It sounds to me like we’re talking about 
policy and civil rights rather than our primary duty, which is transfusion safe-
ty.” Id. (quoting Dr. Susan Leitman). 
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willingness to consider a policy alteration, the FDA’s position 
on HIV and the gay male population has not changed.
70
 
The FDA’s assertions regarding HIV infections in the gay 
male population are not completely unfounded. Despite years of 
prevention and HIV awareness efforts and improved testing 
technology, the HIV infection rate in the U.S. has remained 
stable.
71
 In addition, early detection, which is critical to control-
ling the epidemic, is potentially challenging due to the window 
of time immediately following infection when testing accuracy 
is low.
72
 Perhaps the most unsettling fact is that young gay men 
are increasingly becoming infected with HIV, despite the fact 
that infection rates remain stable.
73
 Of the 47,500 Americans 
who were infected with HIV in 2010, 26% were adolescents or 
young adults aged 13–24.
74
 More disheartening is the fact that, 
from 2008 to 2011, young MSM (aged 13–24) accounted for the 
greatest percentage increase in diagnosed HIV infection.
75
  
The gay community also remains the predominant popula-
tion affected by HIV/AIDS.
76
 In 2010, the MSM population ac-
counted for 63% of new infections, whereas the heterosexual 
population accounted for 25% and the intravenous drug using 
population accounted for 11%.
77
 In 2010, the young MSM popu-
lation experienced a 22% increase in the number of new HIV 
infections, which again was attributed to lack of understanding 
of the risk of HIV.
78
 Still, though the FDA and blood banks re-
main responsible for maintaining the integrity of the blood 
supply,
79
 a substantial portion of those in the medical
80
 and le-
gal
81
 communities maintain that the lifetime ban is now based 
 
 70. Id. 
 71. Kain, supra note 56. 
 72. Id.  
 73. NAT’L CTR. FOR HIV/AIDS, VIRAL HEPATITIS, STD, & TB PREVENTION, 
CDC, CS249858, HIV AND YOUNG MEN WHO HAVE SEX WITH MEN 1–2 (2010) 
[hereinafter HIV AND YOUNG MEN], available at http://www.cdc.gov/ 
healthyyouth/sexualbehaviors/pdf/hiv_factsheet_ymsm.pdf (suggesting that 
this is a result of complacency in the younger generations). 
 74. Id.  
 75. Id. This amounts to around 12,000 young men each year. Further, 
93% of HIV infections among males aged 13–19 are attributed to male-to-male 
sexual contact. Id.  
 76. CDC, NEW HIV INFECTIONS IN THE UNITED STATES 1 (2012).  
 77. Id. at 2.  
 78. Id.  
 79. See Jan M. Bennetts, AIDS: Blood Bank Liability, 27 WILLAMETTE L. 
REV. 355, 372 (1991); Dorney, supra note 36. 
 80. See, e.g., Mohney, supra note 11.  
 81. See, e.g., Casey, supra note 34. 
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on outdated science and old methods of determining one’s HIV 
status, and is consequently bad law.
82
 This is relevant because 
in the past, courts have indicated that laws enacted when cer-
tain facts were relevant may be challenged by a showing that 
the facts no longer exist, a principle that could be applied to the 
FDA’s ban.
83
 
The political climate, now more than ever, warrants that 
the policy be closely scrutinized. The FDA’s policy on MSM do-
nations has incited anger in the LGBT population, and has 
achieved a place in the national spotlight approaching that of 
the marriage equality discussion.
84
 Furthermore, recent court 
decisions across the country have changed the legal landscape 
for sexual orientation-based laws and legal challenges.
85
 Thus, 
the time is ripe (at least, politically) for doing away with the 
ban altogether. 
Politics and policy aside, however, medical breakthroughs 
have vastly improved the landscape of HIV/AIDS treatment, 
detection, and prevention. The combination of several factors, 
such as a better understanding of HIV and HIV/AIDS detec-
tion, concerns for equal protection for LGBT citizens, and the 
harsh realities of the continuing HIV epidemic, produces a dif-
ficult legal and practical question. How do we protect the na-
tion’s blood supply, curb the spread of HIV, and still maintain 
the integrity and constitutional rights of the LGBT population? 
The following Part attempts to address this question and its 
implications. 
II.  ANALYSIS OF THE GAY BLOOD BAN   
Though the FDA’s blanket ban on MSM blood donations 
gained momentum as a viable way to keep the nation’s blood 
supply “clean,” the advent of technology and understanding of 
the disease has led to the regulation’s growing unpopularity.
86
 
And though opposing the ban is a popular political position to 
 
 82. Id. at 553 (arguing for a one-year deferral period).  
 83. See United States v. Carolene Prods. Co., 304 U.S. 144, 153 (1938) 
(“[T]he constitutionality of a statute predicated upon the existence of a partic-
ular state of facts may be challenged by showing to the court that those facts 
have ceased to exist.” (citing Chastleton Corp. v. Sinclair, 264 U.S. 543, 548–
49 (1924))). 
 84. See, e.g., Alissa Scheller & Anna Almendrala, Why Even a 12-Month 
Ban on Blood Donations from Gay Men Makes No Sense, HUFFINGTON POST 
(Dec. 23, 2014, 9:33 PM EST), http://www.huffingtonpost.com/2014/12/23/gay 
-blood-ban-deferral_n_6374374.html.  
 85. See infra Part II.C.  
 86. See supra notes 59–60 and accompanying text. 
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take, there is a dearth of legal scholarship that meaningfully 
addresses the policy in light of modern case law pertaining to 
sexual orientation. However, that is not to say that legal chal-
lenges to the ban have not been contemplated by academics and 
practicing attorneys.
87
 
The normative arguments against the ban are much more 
cognizant of changing attitudes
88
 and the need for a safe and 
adequate national blood supply. One source recently published 
a piece arguing for a complete lift of the ban, citing the “change 
in technology” as the primary evidence for its argument.
89
 
There is merit in this proposal. With new testing, it takes 
around ten days after unsafe sex to conclusively determine 
whether the individual has HIV—and thus whether the blood 
sample is viable or not.
90
 Furthermore, within that ten-day 
window, the chances of a false negative are about one in two 
million.
91
 If every man who engaged in unsafe sex with another 
man were tested, it would make sense to change the ban to a 
deferral period of ten days after having engaged in unsafe sex.
92
 
Regardless, much uncertainty has been removed from the blood 
screening process. Ultimately, it may be the normative argu-
ments that help the hypothetical court in its decision.  
 
 87. The most recent piece regarding the gay blood ban inappropriately 
addresses the situation and, though well-intentioned, comes to an inadequate 
and perhaps incorrect conclusion. Ryan H. Nelson, An Indirect Challenge to 
the FDA’s “Gay Blood Ban,” 23 TUL. J.L. & SEXUALITY 1 (2014). Nelson offers 
what he calls a “weapon in the fight against the gay blood ban: an indirect, 
state-law challenge.” Id. at 3. His solution to the problem only involves indi-
rect challenges on the state level on the basis of “places of public accommoda-
tion” discrimination, which even he admits is impractical unless undertaken 
in litigation nationwide. Id. at 16. Further, his vision of a “threat of such an 
unthinkable, catastrophic blood shortage” resulting from this litigation pres-
suring the FDA into changing its policies is somewhat disturbing. Id.  
 88. For example, many HIV-centric laws concern only gay men, including 
HIV criminalization crimes. See, e.g., Buchanan, supra note 46, at 1240 (“[T]he 
seemingly arbitrary ways in which HIV crimes diverge from their public 
health rationale tend systematically to construct HIV as fairly benign when 
contained within stigmatized populations such as sex workers, intravenous 
drug users, and men who have sex with men. At the same time, these laws 
tend to criminalize the conduct of HIV-positive people when their behavior 
causes anxiety to more privileged heterosexuals, even when it poses no trans-
mission risk.” (footnote omitted)). 
 89. Darling, supra note 44 (stating that inaccurate and slow testing pro-
cesses are a thing of the past “thanks to a faster and far more accurate process 
called Nucleic Acid Testing—NAT, for short,” and that, “[u]nlike the EIA [en-
zyme immunoassays] test, the NAT can detect the amount of actual virus in 
the bloodstream, not just the antibodies produced to fight it”).  
 90. Id.  
 91. Id. 
 92. Id. 
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The most popular challenge to the ban is rooted in admin-
istrative procedure.
93
 As an administrative agency, the FDA 
must follow certain rules in order for its regulations and guide-
lines to be binding on the public. Generally, to be binding, the 
agency must give notice of the proposed regulation and publish 
it in the Federal Register, including specific information for the 
public regarding the regulation, and may only circumvent the 
process in limited circumstances, as set forth in the Adminis-
trative Procedure Act (the APA).
94
 Challengers argue that the 
MSM policy runs afoul of these procedural requirements.
95
 
However, the key piece is missing from these arguments: 
whether or not the FDA would even be able to change its policy 
or an interpretation of its own rule, without going through the 
arduous notice and comment procedure.
96
 Both questions may 
be rendered moot by the FDA’s willingness to proceed with the 
notice and comment process.  
The FDA ban has also undergone criticism on the basis 
that it violates the federal Constitution’s Equal Protection 
Clause.
97
 There is little scholarship today that truly scrutinizes 
the policy adequately in light of recent developments in sexual 
orientation jurisprudence. Specifically, existing scholarship on-
ly analyzes the ban in light of Lawrence v. Texas,
98
 a critical 
case that has since been superseded by subsequent case law 
that potentially expands its holding.
99
 Given recent develop-
ments in civil rights jurisprudence, a constitutional challenge 
to the FDA gay blood ban is more viable than it was in years 
 
 93. For a general discussion on the binding effects of federal agency rules 
and guidelines, see generally Robert A. Anthony, Interpretive Rules, Policy 
Statements, Guidances, Manuals, and the Like—Should Federal Agencies Use 
Them To Bind the Public?, 41 DUKE L.J. 1311 (1992). 
 94. See 5 U.S.C. § 553 (2012).  
 95. See Casey, supra note 34, at 567.  
 96. There was previously a debate, to be discussed infra Part II.A, as to 
whether an administrative agency must alter its initial interpretation of a 
regulation by the same means of modifying the regulation itself, through the 
process of notice-and-comment rulemaking. See generally Paralyzed Veterans 
of Am. v. D.C. Arena L.P., 117 F.3d 579, 586 (D.C. Cir. 1997) (holding that 
agencies must go through notice and comment to change their interpretations 
of regulations).  
 97. See Michael Christian Belli, The Constitutionality of the “Men Who 
Have Sex with Men” Blood Donor Exclusion Policy, 4 J.L. SOC’Y 315, 319 
(2003). 
 98. 539 U.S. 558, 558 (2003) (holding, inter alia, that sexual conduct be-
tween two consenting adults is protected by the Fourteenth Amendment). 
 99. For a pre-Lawrence analysis of the ban, see generally Belli, supra note 
97. See also United States v. Windsor, 133 S. Ct. 2675, 2695 (2013) (expanding 
on Lawrence).  
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past. In fact, the constitutional challenge to the ban is now the 
most important—and viable—challenge to the ban, and as 
such, this Section will focus on those arguments. 
This Note will primarily address the constitutional prob-
lems with the ban—either in its current state or as it would ex-
ist in the form of a one-year deferral period. However, Section A 
addresses why the ban should be lifted from a normative 
standpoint. Section B briefly addresses the procedural chal-
lenge to the ban and its current (lack of) viability.
100
 Section C 
delves into the larger constitutional issues of the policy, taking 
the analysis further than past scholarship in light of recent 
court decisions. This Part seeks to demonstrate conclusively 
that the legal justifications for ending the current policy should 
lead to a new regulatory framework that protects the interests 
of both the FDA and the MSM population. 
A. THE NORMATIVE QUESTION: WHY BOTHER?  
Before addressing how the ban might be challenged, it is 
important to understand why the ban should be lifted. This sec-
tion seeks to answer that question. Why should we challenge a 
law that, from a lay perspective, inconveniences a minute por-
tion of the population? The answer involves a balancing act the 
government should strive for: protecting the national blood 
supply while preserving the dignity of its citizens. Understand-
ing why the ban should be lifted, as well as what an ideal policy 
might strive to accomplish, is crucial in understanding how to 
challenge it. Subsection 1 addresses the need to protect the 
blood supply and Subsection 2 addresses the protection of mi-
nority interests.  
1. Protecting the Integrity of Our Blood Supply  
Ideally, an FDA guideline regarding blood donor require-
ments would adequately preserve the integrity of the nation’s 
blood supply. Protecting the blood supply has two components. 
First, ensuring an adequate supply must be accomplished 
through sensible donation policies that allow for as large a do-
nation pool as possible. Second, the right steps must be put in 
place to ensure that the blood supply remains “clean.” This 
Subsection addresses each of these concerns in turn and deter-
mines that the current guideline fails to address them.  
 
 100. However, as the Note will discuss, many of the procedural problems 
with the current policy would be ameliorated if it is modified subject to a prop-
er notice-and-comment rulemaking process.  
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Doubts abound as to whether the current law is too restric-
tive in its attempts to keep the blood supply “clean.” As estab-
lished earlier, many in the medical profession no longer consid-
er the ban to be based on sound science.
101
 Further, the FDA’s 
assertion concerning the adequacy of our nation’s blood supply 
may not be entirely accurate.
102
 Not all blood is created equal, 
and while asserting that in the aggregate no shortage exists, 
blood type shortages may still exist. Thus, the focus of expand-
ing the pool of donors must address quality as well as quantity.  
The rarest blood type, AB–, is represented in approximate-
ly 1.6% of our population.
103
 While considered the “universal re-
cipient” blood type, AB– is still a valuable potential source of 
blood donation, as are other rare types.
104
 The MSM population 
contains individuals with rare blood types that are underrepre-
sented in the aggregate blood supply.
105
 Thus, though the quan-
titative supply may be adequate, that says nothing of rare 
blood, nor does the FDA address potential MSM donors with 
rare blood types that are not able to donate. Adding otherwise 
viable MSM to the pool of donors has the potential to signifi-
cantly ameliorate blood shortage problems.
106
 
In addition to potentially curtailing the qualitative blood 
supply, the current policy also restricts the quantitative supply. 
As established before, the American Medical Association and 
the Red Cross report that the current ban is unwarranted, and 
 
 101. See Mohney, supra note 11. 
 102. See supra text accompanying note 65. 
 103. See Blood Types, AM. RED CROSS, http://www.redcrossblood.org/learn 
-about-blood/blood-types (last visited Apr. 20, 2015). That is a general esti-
mate, and some sources put the actual number of AB– individuals much lower. 
See Blood Type Chart, NEW HEALTH GUIDE, http://www.newhealthguide.org/ 
Blood-Type-Chart.html (last updated Apr. 20, 2015). 
 104. See 56 Facts About Blood and Blood Donation, BLOOD CTRS. PAC., 
http://www.bloodcenters.org/blood-donation/facts-about-blood-donation (last 
visited Apr. 20, 2015).  
 105. There are, in fact, gay men with rare and useful blood types who 
would like to donate but nevertheless are barred from doing so. Interview with 
Michael Petre, Student, Univ. of Minn. Law Sch., in Minneapolis, Minn. (Mar. 
30, 2014) (stating his blood type to be O–, a rare blood type usually in short 
supply and among the more useful blood types in donor compatibility). Some 
blood types, such as the type O–, are represented by minute portions of the 
population, and individuals with those blood types have very low odds of find-
ing a compatible donor. See Blood Type Chart, supra note 103 (showing that 
Type O– individuals represent 6.5% of the population and have only a 7% 
chance of finding a compatible donor).  
 106. See NAOMI G. GOLDBERG & GARY J. GATES, WILLIAMS INST., EFFECTS 
OF LIFTING BLOOD DONATION BANS ON MEN WHO HAVE SEX WITH MEN 1–2 
(2010), available at http://williamsinstitute.law.ucla.edu/wp-content/uploads/ 
Gates-Goldberg-MSM-Blood-Ban-Jun-2010.pdf. 
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contributes to blood shortages.
107
 Further, though the aggregate 
blood supply may generally be sufficient by some standards, 
the blood supply in certain markets experiences frequent 
shortages.
108
  
Moreover, recent studies indicate that, if the MSM lifetime 
were changed to a twelve-month deferral period, 53,269 addi-
tional MSM would likely donate, leading to approximately 
89,716 extra pints of blood in the blood supply per year.
109
 The 
number increases to 130,150 additional donors and 219,200 ad-
ditional pints when the ban is lifted in its entirety.
110
 Using fig-
ures given by the American Red Cross as to how many lives one 
donor can potentially save, an additional 219,200 donated pints 
of blood translates to potentially 657,600 lives saved per year.
111
 
These numbers indicate that a total lift in the ban (not the 
FDA’s proposed one-year deferral) would result in the national 
blood supply increasing by as much as 1.4%.
112
 Such powerful 
statistics demonstrate that there is a clear and tangible benefit 
to allowing the MSM population to donate, without a re-
striction based on sexual orientation. Therefore, a better donor 
guideline would attempt to increase the donor pool, and one 
way to do that would be to lift the ban entirely. 
That being said, the ideal policy would also protect the 
blood supply from contamination. Modern medical science indi-
cates that the problem of contamination is not nearly as dire 
now as it was in the past.
113
 Further, medical technology has 
reached a point where the current FDA gay blood ban is “anti-
 
 107. Id. at 1.  
 108. See generally Darling, supra note 44 (explaining that blood shortages 
in 2000 caused surgeries to be postponed in some major cities); 56 Facts About 
Blood and Blood Donation, supra note 104 (noting that blood shortages “hap-
pen during the summer and winter holidays”). 
 109. GOLDBERG & GATES, supra note 106, at 2. Were the approximately 7.2 
million men reporting having had another male sexual partner since the age of 
eighteen allowed to donate blood, the study demonstrates that the total dona-
tions would clearly increase even if only a fraction of these men chose to do-
nate. 
 110. Id. at tbl.2. 
 111. According to the American Red Cross, a one pint donation can save up 
to three lives. Blood Facts and Statistics, AM. RED CROSS, http://www 
.redcrossblood.org/learn-about-blood/blood-facts-and-statistics (last visited 
Apr. 20, 2015).  
 112. See GOLDBERG & GATES, supra note 106, at 2 (“While these increases 
in the blood supply may seem modest, they would occur in an environment 
where blood supply shortages are common.”). 
 113. See Mohney, supra note 11 (arguing that the ban is “outdated in light 
of medical advances that can detect HIV in donated blood in nearly all blood 
donations” (emphasis added)).  
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quated” and does little else than keep potential units of viable 
blood from entering the blood supply.
114
 While the FDA and 
blood banks had no way of detecting HIV in the blood prior to 
March of 1985, technology has advanced to the point where all 
blood is routinely screened for various diseases including 
HIV.
115
 Further, given the uses of the NAT test, ten days to two 
weeks is the approximate amount of time it takes to detect HIV 
in the blood following initial infection.
116
 Taking medical devel-
opments into account, the current policy is outdated and should 
be replaced by one that falls more in line with available tech-
nology. 
2. Preserving the Dignity of All Citizens 
Finally, the FDA should strive to protect the dignity of 
United States citizens, in this case, the gay male population. 
The word “dignity” should not only be taken to mean freedom 
from embarrassment in this circumstance, but should include 
acting on moral impulses that contribute to societal good. Take, 
for example, David Dassey, a healthy, HIV-negative 62-year-old 
gay man.
117
 Dassey experienced first-hand the Boston Marathon 
terrorist attacks as a participant in the race and, despite the 
dire circumstances, devastation, and loss of life, he was unable 
to donate blood to save lives in the midst of that crisis.
118
 The 
ban was enforced even in emergency circumstances. Experienc-
es like Dassey’s are not uncommon. Whether out of a sense of 
duty or during times of crisis, gay men nationwide are being 
denied the chance to save lives due to a guideline the American 
Medical Association claims is “discriminatory.”
119
 Again, there 
are many gay men with useful and rare blood types who are not 
allowed to donate, despite being perfectly healthy.
120
  
Taken as a whole, the FDA’s gay blood ban is yet another 
policy that excludes a minority segment of the population from 
participating in activities based not on their illness or level of 
risky behavior, but rather on an inherent trait that exists inde-
pendently of risk.
121
 Even the proposed one-year deferral would 
 
 114. See id.  
 115. See Darling, supra note 44.  
 116. Id. 
 117. Id. 
 118. Id. 
 119. See Mohney, supra note 11. 
 120. See supra note 105 and accompanying text. 
 121. Despite FDA statements to the contrary, see FDA Guidelines, supra 
note 7, the FDA ban excludes based on sexual orientation and not on the risk-
iness of sexual behavior. See supra note 5 and accompanying text. 
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have a similar effect.
122
 Therefore, the ideal policy would take 
into account the dignity of the MSM population while simulta-
neously ensuring an adequate, clean blood supply. Given the 
current state of medical technology, such a solution (that does 
not involve a qualification based on or affecting sexual orienta-
tion) is viable. 
B. THE ADMINISTRATIVE PROCEDURE QUANDARY 
Historically, the procedural challenge to the ban was the 
most popular.
123
 Though the FDA has the power to regulate the 
nation’s blood supply, all regulations must conform to federal 
guidelines on agency rulemaking governed by the APA.
124
 In or-
der for proposed rules to have a binding effect, general notice of 
the proposed rule must be published in the Federal Register, 
and must include specific information for disclosure to the pub-
lic (this is widely known as notice-and-comment rulemaking).
125
 
Exceptions to this rule apply (1) when the agency intends the 
rule to be an interpretive rule, general statement of policy, or 
other policy that does not bind the public, or (2) if the agency 
for “good cause” finds that notice and comment procedures are 
impracticable or unnecessary.
126
 The courts construe these ex-
ceptions narrowly and only recognize them reluctantly so as to 
preserve the public benefit of the statute.
127
 Therefore, any fed-
eral agency rulemaking that fails to satisfy the notice-and-
comment procedure and fails to satisfy either of the two excep-
tions—nonbinding intent or good cause—is not binding on the 
public.  
Recent developments have prompted the FDA to consider 
altering, but not rescinding the ban, which renders a lengthy 
procedural discussion moot. However, this Note will briefly dis-
cuss prior scholarship to both give legal context to the old pro-
cedural argument, and to demonstrate why such a challenge 
would never have been a sufficient means by which to perma-
 
 122. One medical expert states, “The one-year deferral notion constitutes 
symbolic progress, but is not any more warranted than a lifetime ban.” 
Scheller & Almendrala, supra note 84. 
 123. See generally Casey, supra note 34 (challenging the procedural validi-
ty of the ban). That viability, however, has been severely undermined by the 
fact that the FDA has now initiated the notice-and-comment process in order 
to change the lifetime ban to a one-year deferral period. See FDA Statement, 
supra note 66. 
 124. See 5 U.S.C. § 553 (2012). 
 125. See id. § 553(b). 
 126. See id. § 553(b)(A)–(B). 
 127. Anthony, supra note 93, at 1323. 
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nently overturn the ban.
128
 Subsection 1 briefly discusses the 
(now outdated) procedural attack on the ban, and Subsection 2 
addresses the insufficiency of a procedural challenge alone. 
1. A Now-Defunct Procedural Challenge  
Many argue that the FDA did not properly publish the 
MSM guideline. The closest it has come to a formerly published 
regulation regarding MSM donors only applied to those who 
were free from “any disease transmissible by blood transfusion, 
insofar as can be determined by history and examinations.”
129
 
Other than this, no regulation conforming to the procedural 
guidelines of § 553 of the APA pertain to the exclusion of par-
ticular groups, including the MSM population.
130
 Prior scholar-
ship has established that the current policy was implemented 
without notice and comment, so it is not necessary to rehash in 
detail that which has already been established.
131
  
Similarly, the old ban did not meet either exception. The 
regulation was never promulgated as a permanent one; it was 
accepted by the general population and blood banks with the 
assurance that it was only a temporary fix.
132
 Public discourse 
clearly accounted for very little in the events that led to institu-
tion of the permanent ban. Due to the controversial nature of 
the ban and the highly un-democratic manner in which it was 
enacted, the FDA likely has no defense for its guideline under 
the good cause exception. In addition, the FDA has never indi-
cated that the policy is meant to be non-binding.
133
 With no pro-
tection from either exception, the gay blood ban would have 
likely been struck down by the courts as an improperly imple-
mented legislative rule if challenged before the FDA’s Decem-
ber 2014 announcement.
134
  
 
 128. And, therefore, why any future challenge to the ban likely cannot rest 
on a procedural or administrative challenge alone, if at all.  
 129. Casey, supra note 34, at 562 (citing 21 C.F.R. § 640.3(b)(6) (2004)).  
 130. See id. 
 131. See id. 
 132. See id. at 555. 
 133. See id. 
 134. See id. at 567. Casey comes to the same conclusion, arguing that the 
rule “lacks a proper procedural foundation.” Id.  
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2. One Step Further
135
 
Proponents of the gay blood ban possibly have one weapon 
in their arsenal: the Paralyzed Veterans doctrine.
136
 While the 
applicability of this doctrine to the FDA ban is only theoretical, 
it could potentially obfuscate any unilateral attempt by the 
FDA to alter or rescind the current ban. Having promulgated 
the gay blood ban pursuant to authority granted it by federal 
statute,
137
 the FDA could, without interference by the courts, 
rescind the ban under the same authority. However, under 
Paralyzed Veterans, the FDA could only change its interpreta-
tion of its rule on who may donate blood “as it would formally 
modify the regulation itself: through the process of notice and 
comment rulemaking.”
138
 This would be yet another obstacle to 
rescinding the ban, if the doctrine applied.
139
  
That would be a tenuous argument at best, since it would 
require a preliminary finding that the ban is an interpretative 
rule,
140
 an unlikely outcome. Second, the doctrine will soon un-
dergo scrutiny at the United States Supreme Court, since there 
is currently a circuit split on the matter.
141
 Ultimately, because 
a court would very likely find the gay blood ban to be legisla-
tive, the Paralyzed Veterans doctrine would have no applicabil-
ity. Either way, supporters of the ban now only have the notice-
and-comment rulemaking process as a means by which to try 
 
 135. Immediately prior to the publishing of this Note, the Supreme Court 
struck down the Paralyzed Veterans doctrine. See Perez v. Mortgage Bankers 
Ass’n, 135 S. Ct. 1199, 1206 (2015) (“The Paralyzed Veterans doctrine is con-
trary to the clear text of the APA’s rulemaking provisions, and it improperly 
imposes on agencies an obligation beyond the ‘maximum procedural require-
ments’ specified in the APA.” (emphasis in original) (citation omitted)). This 
decision does not meaningfully impact the formerly defective legitimacy of the 
ban, nor does it affect the ultimate analysis or proposal of this Note. 
 136. Paralyzed Veterans of Am. v. D.C. Arena L.P., 117 F.3d 579, 586 (D.C. 
Cir. 1997) (holding that agencies must go through notice-and-comment to 
change their interpretations of regulations). 
 137. See supra note 35. 
 138. Paralyzed Veterans, 117 F.3d at 586. 
 139. Alternatively, an opponent of the ban could argue that the current pol-
icy is in violation of Paralyzed Veterans insofar as it adds the MSM population 
to existing rules on who can and cannot donate.  
 140. See Paralyzed Veterans, 117 F.3d at 586. If the Supreme Court were to 
uphold the doctrine, then interpretative rules would necessarily undergo for-
mal notice-and-comment procedures every time an agency wished to change 
its interpretation of an already-implemented rule.  
 141. See Brief for Petitioners at i, Nickols v. Mortgage Bankers Ass’n, (No. 
13-1052), 2014 WL 4181711, at *1, petition for cert. granted, No.13-1052, 2014 
WL 834024 (June 16, 2014). For the D.C. Circuit opinion that was challenged 
and subsequently reversed, see Mortgage Bankers Ass’n v. Harris, 720 F.3d 
966 (D.C. Cir. 2013). 
2384 MINNESOTA LAW REVIEW [99:2363 
 
and keep the ban in place. Paralyzed Veterans would likely not 
serve either opponents or proponents, given recent develop-
ments and the fact that the FDA will soon utilize the proper 
tools to potentially change the ban.  
Prior scholarship does provide an argumentative frame-
work by which the ban may be defeated in the courts,
142
 but the 
arguments, though persuasive, do not go far enough in address-
ing the underlying issues of the gay blood ban. At any rate, the-
se arguments are more or less outdated in light of the FDA’s 
decision to reconsider the lifetime ban.
143
 
While the procedural challenge to the FDA’s ban is a sig-
nificant step in the right direction, it does not take into account 
the underlying issue of constitutionality. Even if a court were to 
hold that the policy is non-binding on the public, this would 
speak nothing of whether the blood ban violates the federal 
Constitution.
144
 As briefly discussed before, if the FDA ban were 
overturned on procedural grounds, that result alone would not 
speak to the law’s substance, only the manner in which it was 
created.  
Further, the FDA is now in the process of implementing a 
similar discriminatory policy following appropriate administra-
tive procedure.
145
 If the policy alteration is implemented proper-
ly, a procedural challenge to the new policy would be an exer-
cise in futility. Therefore, a proper challenge to the blood ban 
must push any procedural arguments to the backburners, so to 
speak, in favor of an argument that speaks directly to the ban’s 
validity—a constitutional challenge.  
C. THE CONSTITUTIONAL INQUIRY 
As the FDA’s gay blood ban has not been formally chal-
lenged in court on constitutional grounds, there is no case law 
directly on point that may inform this analysis. Nevertheless, 
constitutional law is now the best and most viable option for 
having the current ban or proposed one-year deferral over-
turned.  
 
 142. See generally Casey, supra note 34 (challenging the procedural validi-
ty of the ban). 
 143. The premise of Casey’s article does predict that the FDA could reduce 
the ban to a one-year deferral period. However, it fails to take into account any 
constitutional arguments in favor of overturning the ban. Id. 
 144. Specifically, the Fifth Amendment. U.S. CONST. amend. V. See discus-
sion infra Part II.C.1. 
 145. See Scheller & Almendrala, supra note 84.  
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The FDA ban explicitly identifies and applies to a particu-
lar population—gay men—as a class.
146
 To that effect, the Due 
Process Clause
147
 and Equal Protection Clause
148
 are each po-
tentially relevant to the analysis, though pursuing one may 
yield more favorable results to litigants than the other. Ulti-
mately, this Note seeks to conclude which of the two doctrines 
would better serve litigants seeking to invalidate the blood ban, 
and will follow the line of analysis best suited to overturning 
the ban on the basis of its unconstitutionality. 
In the past, the Due Process Clause and the Equal Protec-
tion Clause were treated very differently, and courts empha-
sized that the Fifth Amendment contained no equal protection 
provision.
149
 However, while courts still hold that the Fifth 
Amendment does not contain an Equal Protection Clause per 
se, current interpretation reflects otherwise.
150
 The Supreme 
Court has gone as far as to state that “the concepts of equal 
protection and due process, both stemming from our American 
ideal of fairness, are not mutually exclusive . . . discrimination 
may be so unjustifiable as to be violative of due process.”
151
 
Thus, either Equal Protection or Due Process can be used to 
challenge the FDA’s gay blood ban (or the potential one-year 
deferral).  
Subsection 1 discusses a challenge under the federal Due 
Process Clause. Subsection 2 delves into the federal Equal Pro-
tection doctrine, which ultimately may be the better basis for a 
challenge to the ban. Subsection 3 brings the analysis to its 
conclusion, and ultimately, this Section concludes that the gay 
blood ban (and the proposed one-year deferral) is not constitu-
tional as it applies to the MSM population. 
1. Due Process  
The Fifth Amendment’s Due Process Clause states that 
“No person shall . . . be deprived of life, liberty, or property, 
without due process of law . . . .”
152
 The Due Process Clause, un-
 
 146. See FDA Guidelines, supra note 7 (noting that the ban applies to “men 
who have had sex with other men”). 
 147. U.S. CONST. amend. V (“No person shall be . . . deprived of life, liberty, 
or property, without due process of law . . . .”). 
 148. U.S. CONST. amend. XIV, § 1 (“No State shall . . . deprive any person 
of life, liberty, or property, without due process of law, nor deny to any person 
within its jurisdiction the equal protection of the laws.”).  
 149. See United States v. Carolene Products Co., 304 U.S. 144, 151 (1938). 
 150. See Bolling v. Sharpe, 347 U.S. 497, 499 (1954).  
 151. Id.  
 152. U.S. CONST. amend. V. 
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like the Fourteenth Amendment, applies to the federal gov-
ernment, so application to the FDA gay blood ban is appropri-
ate without rehashing in detail the analysis in Bolling v. 
Sharpe.
153
 Potentially discriminatory laws—those that curtail 
personal liberty of a class—are properly analyzed under the 
Fifth Amendment. Discrimination, if it is unjustifiable, may vi-
olate the Due Process Clause.
154
 Specifically, the FDA ban, like 
any other potentially discriminatory law, would be challenged 
as violating substantive Due Process, as opposed to procedural 
Due Process.
155
  
A substantive Due Process challenge will stand if it affects 
or unduly burdens a property or liberty interest, but courts do 
not treat all interests the same.
156
 If a law affects a fundamen-
tal liberty or right, then it will be subjected to strict scrutiny 
and upheld only if the law is necessary and narrowly tailored to 
achieve a compelling government interest.
157
 Otherwise, the 
lesser “rational basis” standard would apply, and courts are 
very unwilling to disturb laws under this standard.
158
 Thus, 
whether the gay blood ban or a one-year deferral would pass 
constitutional muster under a Due Process analysis depends on 
whether it affects a fundamental “liberty” or right. 
 
 153. Bolling, 347 U.S. at 497. The analysis in Bolling is more relevant to, 
and will be discussed in, the following section on Equal Protection. See discus-
sion infra Part II.C.2. But for the purposes of Due Process, the Fifth Amend-
ment’s Due Process Clause appropriately applies to the FDA’s regulation, be-
ing a creation of a federal agency. 
 154. Bolling, 347 U.S. at 499.  
 155. Substantive Due Process issues arise when the regulation or law itself 
deprives the individual of property or liberty interests. See generally Lawrence 
v. Texas, 539 U.S. 558 (2003) (discussing substantive Due Process). On the 
other hand, procedural Due Process requires that “an individual be given an 
opportunity for a hearing before he is deprived of any significant property in-
terest.” Cleveland Bd. of Educ. v. Loudermill, 470 U.S. 532, 542 (1985). Thus, 
the issue in a procedural Due Process analysis is whether the victim was af-
forded the appropriate hearing or process due under the law. Id. And while, in 
theory, a procedural Due Process claim could have potentially been made 
against the FDA for the improperly implemented lifetime ban, supra Part II.B, 
such an argument is tenuous and likely irrelevant in light of recent develop-
ments. 
 156. See, e.g., United States v. Windsor, 133 S. Ct. 2675, 2695 (2013) (“The 
liberty protected by the Fifth Amendment’s Due Process Clause contains with-
in it the prohibition against denying to any person the equal protection of the 
laws.”).  
 157. See Planned Parenthood v. Casey, 505 U.S. 833, 929 (1992). 
 158. See Romer v. Evans, 517 U.S. 620, 631 (1996) (“[I]f a law neither bur-
dens a fundamental right nor targets a suspect class we will uphold the legis-
lative classification so long as it bears a rational relation to some legitimate 
end.”). 
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The term liberty as it applies to the Due Process Clause en-
joys a liberal interpretation, encompassing “the full range of 
conduct which the individual is free to pursue.”
159
 Surely donat-
ing blood—contributing to the nation’s blood supply and thus 
national health—is more than a casual activity. For some, the 
act of donating blood is a serious moral obligation. At the very 
least, the act of donating contributes to a utilitarian “greater 
good,” that of keeping the nation’s blood supply at adequate 
levels.
160
 Donating blood is a serious act of giving, even poten-
tially life-saving, that requires a great deal of contemplation, 
and thus a court may reasonably find that donating blood may 
fall into the “full range” of personal conduct individuals are free 
to pursue.
161
 
Assuming that donating blood is a liberty under the Due 
Process Clause, then no law may impede this liberty unless 
pursuant to a rational governmental objective.
162
 Further, if the 
law is restrictive, it must not be an “arbitrary deprivation.”
163
 
Because the FDA ban applies to MSM as a class, it would most 
likely be subjected to some form of heightened scrutiny in 
court.
164
 The government interest is legitimate—the protection 
of our nation’s blood supply from HIV/AIDS was the genesis of 
the law—and for a while it was the best method of doing so.
165
 
However, the scientific and political landscape of our nation 
has changed since the regulation was implemented.
166
 New 
methods of HIV detection are available, methods that are faster 
and more accurate than those available at the time of the 
ban.
167
 Thus, the FDA’s regulation is not narrowly tailored to 
achieve what it sets out to do, but rather, only rests upon “hy-
pothetical justifications” that are incorrect in light of current 
science and medicine.
168
 
 
 159. Bolling, 347 U.S. at 499. This “free range” of conduct encompasses 
more than mere freedom from “bodily restraint.” It implicates the freedom 
from government interference in daily life, absent a proper governmental ob-
jective. Id. at 499–500. 
 160. This is especially so given recent concerns over blood shortages in ma-
jor cities. See infra note 197. 
 161. Bolling, 347 U.S. at 499. 
 162. See id. at 499–500. 
 163. See id. at 500. 
 164. See infra note 211 and accompanying text. 
 165. See supra Part I.A. 
 166. See supra Part I.B.  
 167. Darling, supra note 44.  
 168. See Bostic v. Schaefer, 760 F.3d 352, 377 (4th Cir. 2014). 
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However, this brief analysis is contingent on the assump-
tion that a court would view donating blood as either a property 
or liberty interest. Currently, no cases or legal authority speak 
to whether donating blood is a liberty or property interest. 
There is much less doubt as to whether donating blood is a 
fundamental right. And because a successful Due Process chal-
lenge hinges on the infringement of a right, this argument is 
likely the weaker one. And if a court wishes to avoid the ardu-
ous task of justifying a holding that donating blood is a funda-
mental right, it could merely bypass that inquiry by stating the 
FDA’s policy doesn’t even pass a rational basis test. 
The Supreme Court has acknowledged that the Due Pro-
cess Clause does not necessarily provide as much protection as 
Equal Protection.
169
 As the Court has long held that the explicit 
guarantee of Equal Protection in federal law applies to the 
Fourteenth Amendment, and given that classifying blood dona-
tion is a tenuous argument, Due Process is likely the “lesser” of 
the two potential avenues by which to challenge the FDA’s do-
nation policy.  
2. Equal Protection 
In principle, the Equal Protection Clause speaks to the is-
sue presented in the gay blood ban, that is, whether equity 
should limit the differential treatment gay and bisexual men 
receive based on their differences from heterosexual men.
170
 It 
has been established that heterosexual women, gay women, 
and heterosexual men are not the target of the ban.
171
 The deci-
sion in Bolling and its progeny long ago established that there 
is an Equal Protection component incorporated into the Due 
Process Clause of the Fifth Amendment, thus affording citizens 
of the United States greater protection under federal law as 
well as state law.
172
 
 
 169. Adarand Constructors, Inc. v. Pena, 515 U.S. 200, 213 (1995) (“Alt-
hough this Court has always understood [the Due Process Clause] to provide 
some measure of protection against arbitrary treatment by the Federal Gov-
ernment, it is not as explicit a guarantee of equal treatment as the Fourteenth 
Amendment . . . .”).  
 170. See generally Derek W. Black, The Constitutional Limit of Zero Toler-
ance in Schools, 99 MINN. L. REV. 823, 868 (2015) (“[E]quity limits differential 
treatment based on immutable, illegitimate, or irrational differences between 
individuals.”).  
 171. See supra Part I.B. 
 172. Specifically, the court in Bolling held that “the concepts of equal pro-
tection and due process, both stemming from our American ideal of fairness, 
are not mutually exclusive . . . [D]iscrimination may be so unjustifiable as to 
be violative of due process.” Bolling v. Sharpe, 347 U.S. 497, 499 (1954). See 
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Since Romer v. Evans, courts generally accept the idea that 
homosexuals as a class fall under the protection of the Equal 
Protection Clause.
173
 Since the decision in Lawrence v. Texas,
174
 
which struck down sodomy laws specifically targeted at same-
sex couples,
175
 courts have extended more protection to homo-
sexuals as a class. This trend continued in the recent United 
States v. Windsor decision, in which the Supreme Court held 
that marriage laws defined exclusively in the context of hetero-
sexual unions were unconstitutional.
176
 It follows that any law 
that either facially discriminates against the LGBT population 
or has the effect of discriminating against them would be sub-
ject to an Equal Protection analysis.  
The Equal Protection analysis is the more effective chal-
lenge to the FDA’s gay blood ban, and this requires a deeper 
analysis. Subpart (a) will examine the discriminatory effect (if 
not purpose) the policy has on the MSM population. Subpart (b) 
will discuss how the overinclusiveness of the policy affects the 
effectiveness and legitimacy of the policy’s goals. Finally, Sub-
part (c) discusses the appropriate level of scrutiny that would 
apply to the policy in an Equal Protection Challenge.  
a. Whether the FDA’s Policy Has a Discriminatory Effect on 
the MSM Population 
The primary issue with using Equal Protection is that the 
FDA policy, either in its current form or its proposed form, does 
not specifically address homosexual or bisexual men.
177
 Thus 
one may argue that, under Romer, the FDA’s policy does not 
target a protected class. However, the analysis does not end 
there. Courts have widely held that facially neutral laws which 
have discriminatory effects or impacts on protected classes will 
also be subject to an Equal Protection analysis.
178
 The FDA’s 
blood ban, either in its current form or under the proposed one-
year deferral, falls under the classification of laws that are not 
 
also Korematsu v. United States, 323 U.S. 214, 235–36 (1944).  
 173. See Romer v. Evans, 517 U.S. 620, 631 (1996) (“[I]f a law neither bur-
dens a fundamental right nor targets a suspect class, [the court] will uphold 
the legislative classification so long as it bears a rational relation to some le-
gitimate end.”). 
 174. 539 U.S. 558 (2003). 
 175. Id. at 579. 
 176. See United States v. Windsor, 133 S. Ct. 2675, 2695 (2013).  
 177. See FDA Guidelines, supra note 7. 
 178. See, e.g., Vill. of Arlington Heights v. Metro. Hous. Dev. Corp., 429 
U.S. 252, 259 (1977). 
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facially discriminatory but which have a discriminatory ef-
fect.
179
 
The FDA policy explicitly prohibits men who have had sex 
with men since 1977 from donating blood.
180
 In practical terms, 
this could cover heterosexual, bisexual, and homosexual men. 
However, the law largely impacts gay men, the very population 
that was associated with the HIV/AIDS epidemic.
181
 In addition, 
the FDA’s MSM policy was specifically implemented to address 
concerns over HIV/AIDS.
182
 Gay and bisexual men inevitably 
represent a tremendous portion of the MSM population, and for 
all intents and purposes define the MSM population.  
The law’s discriminatory impact does not change even if 
the FDA’s recommended one-year deferral period is implement-
ed, because it also uses the MSM population as a starting point 
by which to weed out potential risky blood donors. For many 
gay men, the FDA’s proposed new policy is just as prohibitive 
as the old one. To put it another way, “[t]he FDA has decided 
that the blood coursing through your veins isn’t a lifetime 
threat to the American public—just a year-long threat.”
183
 The 
one-year deferral would do little to change that perception. In 
fact, maintaining a ban in some form effectively perpetuates 
negative stereotypes and stigmas attached to gay and bisexual 
men by basing donor guidelines on stereotypes, not science.
184
 
The discriminatory effect and intent are more pronounced 
when available science is taken into consideration.
185
 The cur-
rent ban and proposed one-year deferral are (and would be) 
written in such a way to suggest some discriminatory or sexual 
 
 179. These laws are also illegal. See generally Yick Wo v. Hopkins, 118 U.S. 
356 (1886) (holding that a law, even if facially neutral, may impose purposeful 
discrimination if it is administered in a discriminatory way).  
 180. FDA Guidelines, supra note 7. 
 181. See supra Part I.A.  
 182. See supra Part I.B. 
 183. John Gallagher, Nine Ways To Avoid Sex for the Next Year So You Can 
Donate a Pint of Blood, QUEERTY (Dec. 31, 2014), http://www.queerty.com/ 
nine-ways-to-avoid-sex-for-the-next-year-so-you-can-donate-a-pint-of-blood 
-20141231 (“[T]o donate blood, you need to get ready now, which means giving 
up sex for a year.”).  
 184. Andrew Cray, Members of Congress Encourage End to Discriminatory 
Blood Donation Policy, THINKPROGRESS (Aug. 5, 2013), http://thinkprogress 
.org/lgbt%20/2013/08/05/2412721/msm-blood-donation. 
 185. Id. (“The absence of a non-discriminatory rationale becomes even 
clearer in light of significant advancements in medical technology and devel-
opments in blood screening and record-keeping since the donation ban was put 
in place 30 years ago. In fact, current blood screening tests are so effective 
that the probability of HIV transmission through blood transfusion is one in 
1.5 million, a significant decrease from risk levels in the mid-1990s.”). 
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orientation-based animus. Further, the policies are part of 
larger fear-based policy-making in response to the HIV/AIDS 
epidemic.
186
 The gay blood ban in any form does not likely fall 
under the type of laws that make classifications serving to pro-
tect legitimate interests, especially given the science that has 
developed since the ban was first implemented.
187
  
With all factors taken into consideration, including the his-
tory of the HIV/AIDS epidemic, the FDA’s initial response by 
way of targeting homosexual men,
188
 and this discussion, a 
court would very likely find both the gay blood ban and the 
proposed one-year deferral to have a discriminatory effect. Fur-
ther, there is a reasonable chance that a court would find it (ei-
ther the current ban or one-year proposal) to have a discrimi-
natory intent, despite the wording of the policy. 
b. Whether the FDA’s Policy Is Overinclusive  
Any time a law is challenged, the government may deflect 
the suit by proving the law is appropriately tailored to further 
some interest.
189
 The FDA would likely argue that the gay blood 
ban meets that criterion under any level of scrutiny.
190
 Howev-
er, one crucial counterargument would be that the ban is 
overinclusive.  
A law is overinclusive if it applies to all people who are 
similarly situated, but also people who should not be included; 
essentially, the law regulates more people than is necessary to 
achieve the government’s purported interest.
191
 Under either a 
rational basis or strict scrutiny test,
192
 some laws are so 
underinclusive (not regulating enough individuals to accom-
plish government objective) or so overinclusive in their classifi-
cation that the distinction “cannot be said” to rationally further 
the posited state interest.
193
  
 
 186. Id. 
 187. See Nordlinger v. Hahn, 505 U.S. 1, 13 (1992). 
 188. Casey, supra note 34, at 554–56. 
 189. See Ry. Express Agency, Inc. v. New York, 336 U.S. 106, 112 (1949) 
(Jackson, J., concurring) (“The burden should rest heavily upon one who would 
persuade us to use the due process clause to strike down a substantive law or 
ordinance.”).  
 190. See infra Part II.C.2.c for a discussion of the standards of scrutiny 
courts apply to these types of constitutional challenges.  
 191. Equal Protection Definition, LEGAL DICTIONARY, http://legal 
-dictionary.thefreedictionary.com/Equal+Protection (last visited Apr. 20, 
2015). 
 192. See Nordlinger, 505 U.S. at 10 (discussing the rational basis and strict 
scrutiny standards). 
 193. Id. at 35 (Stevens, J., dissenting).  
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If a law is overinclusive, specifically, a court will invalidate 
it if it “sweeps too broadly and operates too indiscriminately” in 
furthering the state’s interest or objectives.
194
 As Justice Ste-
vens wrote, “[i]t is just short of absurd to conclude that the le-
gitimate state interest in [regulating] a relatively small num-
ber” of risky individuals is rationally furthered by regulating a 
significantly wider population.
195
 
Blood banks’ opposition to the FDA’s gay blood ban illus-
trates this principle.
196
 The American Red Cross, for example, 
has publicly argued against the lifetime ban on the grounds 
that it contributes to blood shortages.
197
 The inability to collect 
the blood of millions of MSM, while not the sole cause of any 
blood shortage, is a contributing factor in the critical problem of 
the blood shortage.
198
 As has already been discussed, while the 
blood supply in the aggregate is not in shortage, this speaks 
nothing of the potential for rare blood-type shortages.
199
 Also 
recall that opening the pool of donors to gay men is estimated 
to save an upwards of 657,600 lives saved per year.
200
 All told, 
the ban does prevent a small portion of a high-risk population 
from donating, but also excludes thousands of otherwise viable, 
healthy donors. 
The biggest factor in the ban’s overinclusiveness is develop-
ing technology. When the ban was first implemented, and little 
was known about HIV, that might have not been the case. But 
as science and society have evolved, the pool of donors at risk 
for HIV infection has narrowed.
201
 The fact that thirty-seven 
states (and counting) now allow gay marriage
202
 has significant-
 
 194. Id. 
 195. Id. at 36–37 (drawing that conclusion as applied to property taxes in 
California).  
 196. It is estimated that, in any given year, more than seven million men 
are prohibited from ever donating blood. Casey, supra note 34, at 567. This is 
not surprising, however. As has been discussed, the concern over blood short-
age has always been the primary objection of blood banks to the FDA policy. 
See Dorney, supra note 36, at 144.  
 197. See Darling, supra note 44 (“In 2000, [blood] shortages led to post-
ponements of elective surgeries in Philadelphia, Atlanta, and Los Angeles. At 
the time, all hospitals combined needed about 80,000 units of blood daily, but 
the Red Cross could deliver only 36,000.”). Id.  
 198. 56 Facts About Blood and Blood Donation, supra note 104 (“[I]f only 
one more percent of all Americans would give blood, blood shortages would 
disappear for the foreseeable future.”). 
 199. See supra Part II.A.1.  
 200. See Blood Facts and Statistics, supra note 111 (finding that a one pint 
donation can potentially save up to three lives a year).  
 201. See supra Part I.B.  
 202. See States, FREEDOM TO MARRY, http://www.freedomtomarry.org/ 
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ly changed society’s perception of the LGBT community. There 
is a discrete group of individuals whose behavior puts them at 
risk, including IV drug users and sharers and those who indis-
criminately have unprotected sex.
203
 Those groups and the 
MSM population are not mutually inclusive, though the policy 
implications of the FDA’s ban would seem to suggest otherwise.  
Whether or not the FDA’s gay blood ban is overinclusive is 
not wholly dispositive of the constitutional issue. Courts apply 
various standards of scrutiny when laws are challenged under 
the Equal Protection Clause, and under the same facts, one 
standard will yield more favorable results than the other. The 
overinclusiveness of the ban is thus tied closely with the stand-
ard of scrutiny that would likely apply.  
c. The Appropriate Standard of Scrutiny 
Though Equal Protection is likely the more effective of the 
two potential constitutional challenges, courts apply varying 
standards of scrutiny when analyzing such challenges and the 
outcome depends heavily on which standard the court chooses 
to use. Essentially, “unless a classification warrants some form 
of heightened review because it jeopardizes exercise of a fun-
damental right or categorizes on the basis of an inherently sus-
pect characteristic, the Equal Protection Clause requires only 
that the classification rationally further a legitimate state in-
terest.”
204
 
The least stringent level of scrutiny is known as rational 
basis, and a law challenged as violating the Equal Protection 
Clause will survive under an Equal Protection analysis if it is 
rationally tailored to further a legitimate state interest.
205
 This 
standard is more widely used, and will only be discarded for 
heightened scrutiny if a state-imposed classification “warrants 
some form of heightened review because it jeopardizes exercise 
of a fundamental right or categorizes on the basis of an inher-
ently suspect characteristic.”
206
 
Strict, or heightened, scrutiny applies where courts find 
the question to be one of equal protection against infringement 
of fundamental rights or discrimination against suspect clas-
ses.
207
 Under the strict scrutiny standard, a law “may be justi-
 
states (last updated Mar. 4, 2015). 
 203. See infra Part III.B.  
 204. Nordlinger v. Hahn, 505 U.S. 1, 10 (1992). 
 205. Id.  
 206. Id. 
 207. See generally United States v. Windsor, 133 S. Ct. 2675, 2716–17 
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fied only by compelling state interests, and must be narrowly 
drawn to express only those interests.”
208
 Further, the govern-
ment bears the burden of satisfying the standard, and must re-
ly on the law’s actual purposes, rather than hypothetical justi-
fications to prevail.
209
 Having historically been applied to cases 
of race and national origin discrimination,
210
 the idea of subject-
ing classifications based on sexual orientation to strict scrutiny 
has grown popular in recent years.
211
  
The Second Circuit explicitly endorsed this line of thought 
by applying strict scrutiny to classifications based on sexual 
orientation.
212
 When that decision made its way to the Supreme 
Court in United States v. Windsor, the Court flirted with the 
idea of applying strict scrutiny and, though it ultimately did 
not explicitly affirm the use of that standard, nevertheless af-
firmed the Second Circuit’s ruling in its entirety.
213
 The Fourth 
Circuit applied strict scrutiny recently to a same-sex marriage 
case, though the court did so because it held marriage to be a 
fundamental right.
214
 Even though strict scrutiny was not ap-
plied on the basis of sexual orientation being a suspect class, 
the court nevertheless came close to doing so.
215
 The Tenth Cir-
cuit has also applied strict scrutiny to cases involving same-sex 
couples.
216
 
The trend is clear: though the Supreme Court has not ex-
plicitly used a strict standard of review for classifications based 
on sexual orientation, its shifting attitude indicates that such a 
standard may become an eventuality, though not an inevitabil-
ity. It is doubtful, though within the realm of possibility, that a 
federal court would decline to use at least some form of height-
ened scrutiny in analyzing a law such as the FDA’s blood dona-
tion policy. 
 
(2013) (discussing when strict scrutiny should apply).  
 208. Bostic v. Schaefer, 760 F.3d 352, 377 (4th Cir. 2014) (quoting Carey v. 
Population Servs. Int’l, 431 U.S. 678, 686 (1977)) (internal quotation marks 
omitted). 
 209. Id. (citing Fisher v. Univ. of Tex. at Austin, 133 S. Ct. 2411, 2420 
(2013); Shaw v. Hunt, 517 U.S. 899, 908 n.4 (1996)).  
 210. See, e.g., Adarand Constructors, Inc. v. Pena, 515 U.S. 200, 222 (1995).  
 211. President Obama in particular is an advocate of applying the height-
ened scrutiny standard to cases involving sexual orientation discrimination. 
See Windsor, 133 S. Ct. at 2683.  
 212. Id. at 2684.  
 213. Id. at 2696. 
 214. Bostic v. Schaefer, 760 F.3d 352, 375 (4th Cir. 2014). 
 215. Id. at 375 n.6. 
 216. See Kitchen v. Herbert, 755 F.3d 1193, 1218 (10th Cir. 2014). 
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A strict-scrutiny analysis would very likely yield favorable 
results to those seeking to have the gay blood ban or one-year 
deferral overturned. The FDA may repeat its argument that 
the MSM population is more at risk of transmitting HIV/AIDS, 
but this argument would be unavailing, as the FDA “cannot 
rest upon a generalized assertion as to the classification’s rele-
vance to its goals.”
217
 In short, the “purpose of the narrow tailor-
ing requirement [in a strict-scrutiny analysis] is to ensure that 
the means chosen fit the compelling goal so closely that there is 
little or no possibility that the motive for the classification was 
illegitimate.”
218
  
As already discussed, the FDA’s current gay blood ban and 
proposed one-year deferral are, as they relate to the goal of 
blood supply safety, impermissibly overinclusive. So under a 
strict-scrutiny analysis, the FDA would likely fail to persuade 
the court to uphold the constitutionality of the gay blood ban. If 
any viable and less discriminatory option for the FDA exists, 
then the court would especially look at the blood ban with a 
wary eye.  
3. Constitutional Conclusions 
The government objective of defending the blood supply 
must remain stalwart, yet this does not save the FDA’s gay 
blood ban or one-year deferral.
219
 With the advent of new tech-
nologies and a greater understanding of HIV, the ban is no 
longer narrowly tailored to achieve a compelling government 
interest,
220
 but now is considered by many, including medical 
experts,
221
 to be arbitrary and based on obsolete science.
222
  
The landmark decision in Windsor struck down the most 
restrictive portion of DOMA.
223
 Gay marriage is now legal in 
 
 217. Id. (quoting Richmond v. J.A. Croson Co., 488 U.S. 469, 500 (1989)) 
(internal quotation marks omitted).  
 218. Id. (quoting Grutter v. Bollinger, 539 U.S. 306, 333 (2003)) (internal 
quotation marks omitted); see also id. (stating that only “the most exact con-
nection between justification and classification” would survive strict scrutiny 
(quoting Gratz v. Bollinger, 539 U.S. 244, 270 (2003) (internal quotation 
marks omitted)).  
 219. This is especially true since the law is now based on scientific facts 
which have ceased to exist and have been replaced by newer understanding of 
the disease. See Scheller & Almendrala, supra note 84. 
 220. See United States v. Windsor, 133 S. Ct. 2675, 2717 (2013). The “nar-
rowly tailored” law achieving a “compelling government interest” is the hall-
mark standard by which a law may survive the strict scrutiny standard. Id. 
 221. See Mohney, supra note 11. 
 222. See id. 
 223. See Windsor, 133 S. Ct. at 2695–96.  
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thirty-seven states.
224
 That two men may legally marry yet be 
considered a high risk of HIV is not patently absurd, but the 
idea of monogamy between same-sex couples is now a socially 
(and in places, legally) recognized relationship, a far cry from 
the environment of the 1980’s. The FDA blood ban (and poten-
tial deferral) does not address MSM who are in monogamous 
relationships and does not consider them to be low-risk indi-
viduals.
225
 With the changing attitudes towards homosexuality, 
same-sex marriage, and new technology, including the NAT 
and antibody tests,
226
 there is no justification, constitutional or 
otherwise, for maintaining the gay blood ban as it is.  
Further, the guideline is likely violative of the federal 
Equal Protection Clause. While this Note cannot make a defini-
tive conclusion as to the outcome of a constitutional challenge 
to the FDA’s gay blood ban or one-year deferral, a successful 
challenge would very likely include arguments that the law, 
though facially neutral, has a discriminatory effect on gay and 
bisexual men as a protected class and is impermissibly 
overinclusive as to be violative of the Equal Protection Clause.  
III.  POTENTIAL EQUITABLE SOLUTIONS   
The challenge to the FDA’s gay blood ban set forth in this 
Note is a comprehensive, direct challenge to the ban. It propos-
es a method by which the ban may be properly challenged, di-
rectly in courts.
227
 By challenging the ban on the basis of its 
constitutional merits, this Note lays the groundwork for chal-
lenging the ban directly. An indirect challenge would not be 
sufficient, as it would not address the ban on its merits.
228
 Prov-
ing the unconstitutionality of the ban is, however, only one of 
this Note’s ultimate goals. Pointing out the unconstitutionality 
of the current and future policy has little utility without sug-
gesting an ideal policy that may be used instead. Section A 
briefly considers what other countries have implemented in 
terms of blood donation guidelines. Section B suggests an effec-
tive and equitable guideline.  
 
 224. See States, supra note 202.  
 225. FDA Guidelines, supra note 7.  
 226. See Darling, supra note 44.  
 227. See supra Part II (discussing constitutional challenges to the FDA’s 
gay blood ban).  
 228. See Nelson, supra note 87, at 16. 
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A. COMPARATIVE APPROACH: WHAT OTHER COUNTRIES HAVE 
DONE 
While maintaining the current gay blood ban cannot stand, 
as it most likely would not withstand constitutional muster, 
eliminating the ban entirely with no other guidelines may have 
troubling consequences.
229
 After all, the rate of HIV/AIDS infec-
tions in the young MSM population is on a steady rise.
230
 How-
ever, testing technology allows banks to determine whether 
blood is infected more inexpensively, more accurately, and more 
quickly.
231
 Therefore, rather than eliminating the ban, a bal-
ance should be struck between preserving the integrity of the 
nation’s blood supply and allowing certain MSM populations at 
low risk for HIV/AIDS infection to donate blood.
232
  
One inquiry that may better inform the problem is a com-
parative approach—to look beyond the borders of the United 
States and evaluate how other countries with less restrictive 
guidelines on blood donations have handled the problem. Note 
that this comparative approach is not a basis for challenging 
the ban. It is a method by which to evaluate the effectiveness 
(or lack thereof) of blood donation policies from other nations.  
Maintaining a deferral period of a year is a popular alter-
native to a lifetime bar, and many countries have done just 
that. Australia, for example, has a one-year ban in place.
233
 
Studies have shown that, for men who are sexually inactive for 
a twelve-month period, there is no increased risk of transfu-
sion-transmitted cases of HIV.
234
 However, while such deferrals 
are more progressive than the current United States regula-
tion, they might lead to extended “dry spells”
235
 on any MSM 
 
 229. See FDA Guidelines, supra note 7. If anything, a questionnaire would 
be critical in ascertaining who may and who may not donate, so as to screen 
potentially high-risk donors.  
 230. HIV AND YOUNG MEN, supra note 73.  
 231. See Kain, supra note 56. 
 232. Low-risk sexual behavior as defined by the FDA (e.g., not having sex 
with prostitutes, not engaging in sexual activity involving intravenous drug 
use, etc.) should be applied to gay men as it is applied to heterosexual individ-
uals. A low-risk MSM may be a gay man in a monogamous marriage, whereas 
a high-risk MSM may be a sex worker.  
 233. Seed et al., supra note 61, at 2722. A one-year deferral essentially al-
lows gay men to donate blood if they have not had sex with other men within 
the past year.  
 234. See id.   
 235. The phrase “dry spell” is a common colloquialism meaning “to go for a 
period of time (usually longer than shorter) without something,” e.g., sex. Dry 
Spell Definition, URBAN DICTIONARY, http://www.urbandictionary.com/define 
.php?term=dry%20spell (last visited Apr. 20, 2015). 
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who ever hopes to donate blood.
236
 And this is the primary ob-
jection to the FDA’s proposed one-year deferral period.  
Other nations have implemented less restrictive laws. De-
claring that “sex between people of the same sex ceases to be 
considered a danger, disease, or infection by the Health Minis-
try,” Chile completely lifted the ban on gay and lesbian do-
nors.
237
 Mexico has also lifted its ban entirely.
238
 Neither ban 
lifts are without qualification: Chile’s new policy bans all peo-
ple, regardless of sexual orientation, from donating blood if 
they have engaged in risky sexual behavior, which is defined as 
sex with more than one partner in the last twelve months.
239
 In 
Mexico, the focus is similarly on risky behavior rather than so-
cial groups.
240
 Gay and bisexual men who have a history of us-
ing condoms, who do not inject drugs, and who are not sex 
workers are eligible to donate blood under Mexico’s new law.
241
 
Heterosexuals are subjected to the same standard,
242
 an im-
portant distinction from the current United States guidelines. 
In the countries that have lifted the ban, there is a clear 
shift in focus. Instead of identifying an individual’s sexual ori-
entation or a specific social group, the laws focus on risky be-
haviors.
243
 In the process of updating their laws, the countries 
with complete ban-lifts used compelling policy arguments in 
regards to ending discrimination.
244
 The countries that have 
ended their bans placed at least some emphasis on the rights of 
minority citizens. The FDA, on the other hand, makes little 
mention of whether its policy is discriminatory.
245
  
 
 236. Though a year-long deferral is clearly preferable to a lifetime ban, the 
practical consequences essentially restrict the sexual activity of the MSM pop-
ulation, especially considering that in some states, gay marriage is legal. The 
hypothetical one-year deferral would lead to an unusual situation for many 
MSM: abstain from sex (even if married) for a year, donate, and then resume 
sexual activity.  
 237. Trovall, supra note 61.  
 238. Roberts, supra note 61.  
 239. Trovall, supra note 61.  
 240. Roberts, supra note 61.  
 241. Id. It should also be noted that the new law is devoid of qualifications 
based on sexual identity. See id.  
 242. See id.  
 243. See, e.g., id.  
 244. See Sunnivie Brydum, Mexico Lifts Blood Donation Ban for Gay and 
Bisexual Men, ADVOCATE (Dec. 28, 2012, 4:32 PM), http://www.advocate.com/ 
health/health-news/2012/12/28/mexico-lifts-blood-donation-ban-gay-and 
-bisexual-men.  
 245. FDA Guidelines, supra note 7 (“FDA’s deferral policy is based on the 
documented increased risk of certain transfusion transmissible infections, 
such as HIV, associated with male-to-male sex and is not based on any judg-
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Excluding the policy justification from the discrimination-
context cannot stand. As the previous section established, there 
are meritorious arguments addressing the discriminatory as-
pect of the FDA ban.
246
 Thus, for a truly equitable solution to 
emerge, evaluation of the ban must follow the model of coun-
tries such as Mexico and Chile and put more emphasis on elim-
inating discriminatory elements within any new guidelines. 
B. A SAFE AND EQUITABLE POLICY SOLUTION 
An ideal donation policy in the United States must main-
tain the integrity of the blood supply and provide equitable 
treatment to the MSM community. Above all, it may not apply 
in unqualified terms to one population or another in order to 
remain consistent with Due Process and Equal Protection.
247
 As 
such, this Note suggests a regulation that allows gay men who 
engage in non-risky sexual behavior to donate blood while 
maintaining safeguards in place to protect the blood supply.  
First, the new regulation must apply to all individuals, 
men and women, regardless of their sexual orientation. Such a 
qualification is arbitrary and potentially unconstitutional, as 
discussed above.
248
 To create a law that is both effective and 
protects the constitutional interests of potential blood donors, 
the United States should look to solutions enacted by other 
countries, such as Chile and Mexico.
249
 Thus, the new guideline 
must shift the focus from sexual orientation to sexual behav-
ior.
250
 The new regulation should take into account current 
medicine and current blood-testing technology.
251
 
Current technology allows for the detection of HIV imme-
diately following infection at around ten days, and two weeks is 
considered a “safe” timeframe.
252
 Because of the timeline in 
which HIV infection occurs and shows up in tests,
253
 all individ-
 
ment concerning the donor’s sexual orientation.”).  
 246. See supra Part II.C. 
 247. See supra Part II.C. 
 248. See supra Part II.C. 
 249. Roberts, supra note 61; Trovall, supra note 61. 
 250. For example, instead of focusing on gay men having sex, shift the fo-
cus to any individual who habitually uses intravenous drugs concurrently with 
sex. 
 251. See Darling, supra note 44. 
 252. Id.  
 253. Id. (“Within seven to 10 days, we can say with 99.9 percent accuracy 
whether or not a blood sample is HIV-positive. The chance of an HIV-positive 
blood sample testing negative after the 7 to-10-day window is about 1 in 2 mil-
lion . . . . [I]f you’ve had unsafe sex within the past 10 days, it might be rea-
sonable for us to send you home. But a lifetime ban . . . is kind of ridiculous.”).  
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uals who have engaged in unsafe sex within fourteen days prior 
to attempted donation should be turned away. This will ensure 
that gay men engaging in “safe” sex, or those who have not, will 
still be eligible at some point in the foreseeable future to donate 
blood. Further, it should be emphasized that rejecting dona-
tions should be the exception: individuals who have a history of 
using condoms, engaging in safe sex, and who have not engaged 
in unsafe sex within the past fourteen days should be permitted 
to donate blood.
254
 This proposed process would impose no addi-
tional burden on blood banks, as they routinely pay for all blood 
screening, using the latest technology at their disposal.
255
 
Defining what constitutes safe sexual activities is critical 
to developing a sound, effective guideline. For example, unsafe 
sex could constitute engaging in unprotected sex with one or 
multiple partners, having sexual relations of any sort with a 
sex worker, and engaging in sexual behavior in concurrence 
with drug use.
256
 However, stipulating the number of sexual 
partners one may have is, so to speak, another can of worms 
that this Note shall not open. Additionally, the definition may 
include stipulations regarding proper condom usage, regardless 
of the sexual partner(s) involved. Such a solution, with the 
fourteen-day deferral period, takes adequate steps to filter out 
high-risk donors and, with the elimination of the MSM desig-
nation, does not run afoul of the due process doctrine.  
Such a new regulation should also follow the proper proce-
dural guidelines for administrative rules, pursuant to the APA, 
so as to not make the same mistakes as the current guideline.
257
 
Specifically, the notice-and-comment requirement, critical to 
preserving the public discourse on rules intended to be binding, 
should be respected in the interest of the democratic process.
258
  
 
 254. Either way, it would seem that the public health policy goals would 
still be maintained with this regulatory framework. The most critical objective 
now is to remove the stigma associated with HIV.  
 255. Blood banks do not only pay for HIV screening, they screen for a host 
of other ailments and viruses, including hepatitis B, hepatitis C, blood that is 
at risk for leukemia or neurological diseases, syphilis, West Nile Virus, and 
bacterial contamination. See Donation FAQs, AM. RED CROSS, http://www 
.redcrossblood.org/donating-blood/donation-faqs (last visited Apr. 20, 2015).  
 256. Such a definition for “unsafe” sexual activities may be taken from def-
initions provided in countries where the focus on donation restrictions is on 
behavior rather than sexual orientation, such as Chile. See generally supra 
Part III.A. 
 257. See generally 5 U.S.C. § 553 (2012) (articulating the rule-making pro-
cedures). 
 258. Cf. Anthony, supra note 93, at 1312 (“To use . . . nonlegislative docu-
ments to bind the public violates the Administrative Procedure Act . . . and 
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This proposed solution is the most equitable. By basing 
guidelines for who may donate on risky behavior rather than 
sexual orientation, the FDA can avoid claims of discriminatory 
policy-making.
259
 With clearly stipulated behaviors (proven to 
be high-risk) that would warrant a temporary deferral from do-
nating blood, the FDA can achieve its goals of protecting and 
growing the national blood supply. The FDA would not only be 
acting pursuant to an unquestionably constitutional regulation, 
but one that increases the availability of blood and protects the 
dignity of the MSM population. 
All of this being said, this Note includes a proposal for 
what a new blood donation guideline might contain. Currently, 
the language of the FDA’s rule states that:  
Men who have had sex with other men (MSM), at any time since 1977 
(the beginning of the AIDS epidemic in the United States) are cur-
rently deferred as blood donors. This is because MSM are, as a group, 
at increased risk for HIV, hepatitis B and certain other infections that 
can be transmitted by transfusion.
260
  
Even the new regulation, with its one-year deferral period, 
looks to contain the exact same language, which substantively 
changes nothing about the discriminatory impact on gay men.
261
 
This language must be eliminated in its entirety, as sexual ori-
entation is an arbitrary method of determining risk.  
Instead, the new regulation should begin with language 
such as: “Individuals who have engaged in sexual behavior 
characterized as risky, unsafe, or dangerous are currently de-
ferred as blood donors.” Removing a label regarding gender, 
sex, or sexual orientation is crucial in ensuring that the new 
rule applies equally to all citizens in accordance with federal 
Due Process and Equal Protection.
262
  
Defining sexually unsafe or risky behavior, as explained 
above, is essential to forming the new rule in a way that best 
protects the nation’s blood supply. Such language might say: 
 
dishonors our system of limited government.”). 
 259. One source points out that, though African-Americans account for a 
large portion of the HIV-positive population, there is no deferral for them and 
that, were such a deferral to be put in place, it would obviously be seen as rac-
ist. Smith, supra note 60.  
 260. FDA Guidelines, supra note 7. 
 261. Donor Deferrals: The FDA’s Blood Policy on Gay Men Falls Short, 
PITTSBURGH POST-GAZETTE (Jan. 4, 2015, 12:00 AM), http://www.post 
-gazette.com/opinion/editorials/2015/01/04/Donor-deferrals-The-FDA-s-blood 
-policy-on-gay-men-falls-short/stories/201501090002 (stating that under the 
potential new policy, “many gay men still won’t be eligible to donate, and the 
nation’s blood supply will continue to suffer for it”).  
 262. See U.S. CONST. amend. V; U.S. CONST. amend. XIV, § 1. 
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“The FDA defines risky, unsafe, or dangerous sexual behavior 
as having engaged in any of the following activities within thir-
ty days of donation: (1) engaging in unprotected sex with one or 
multiple partners; (2) engaging in protected or unprotected sex 
with a sex worker; (3) engaging in protected or unprotected sex 
in concurrence with intravenous or otherwise illegal drug use. 
‘Unprotected’ sex is commonly understood to mean having sex 
without the use of a condom and/or a diaphragm.” This lan-
guage is a more accurate representation of what populations 
present the most risk to the blood supply than does the current 
FDA rule. Adding sixteen days to the fourteen day “safety” 
window is designed to provide an extra level of reassurance 
that the screened blood is truly safe.
263
  
The language contained within this proposed regulations 
accomplishes what the FDA should have set out to do when it 
first implemented the gay blood ban. It applies to individuals in 
a manner that is not discriminatory because it does not identify 
at-risk individuals by their sex, gender, sexual orientation, and 
so on. Second, it provides a more than adequate level of protec-
tion for the blood supply by clearly defining sexually risky be-
havior that is likely to result in an infection with HIV, hepatitis 
B, and other serious illnesses. With a blood donation guideline 
containing this language, the FDA would finally have a rule 
that is properly tailored to achieve its interests and the inter-
ests of the LGBT community. 
  CONCLUSION   
The United States has a long and wearied history with the 
HIV/AIDS epidemic.
264
 The fight against the epidemic still con-
tinues, with the rates of young MSM infections on the rise and 
overall infection rates remaining stable.
265
 Nevertheless, the 
FDA’s current policy on blood donation, though implemented at 
a time when it was a logical solution, is no longer sensible.
266
 In 
fact, the policy, in light of technological developments,
267
 chang-
ing social attitudes, and increasing legal rights for the LGBT 
 
 263. And to an individual wishing to donate blood, this is a much less bur-
densome requirement. For example, a gay man wishing to donate under the 
current ban cannot if he has ever had sex. Under the proposed regulation, the 
burden would mean waiting a year. But if, for instance, this ideal regulation 
were implemented, a donor would have to wait a mere thirty days if he or she 
engaged in risky behavior. 
 264. See A Timeline of AIDS, supra note 17.  
 265. HIV AND YOUNG MEN, supra note 73.  
 266. See supra Part II.B. 
 267. See Mohney, supra note 11. 
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population
268
 is not only arbitrary, it may lead to ridiculous re-
sults.
269
  
A sensible solution for the modern world would apply to all 
people regardless of sexual orientation, implement a reasonable 
deferral period for those who have engaged in unsafe sex, and 
take into account the current technology and attitudes of today. 
A new policy is clearly needed so that those individuals like 
Campbell, California Mayor Evan Low
270
 and other healthy gay 
men who would otherwise be perfect donors were it not for the 
capricious ban, may one day be allowed to participate in a sys-
tem which saves lives on a daily basis. 
 
 
 268. See Sievers, supra note 3.  
 269. See, e.g., Darling, supra note 44.  
 270. Vongsarath, supra note 1.  
